Frank L. Jaksch, Jr. Sells 37,161 Shares of ChromaDex Co. (NASDAQ:CDXC) Stock

ChromaDex Co. (NASDAQ:CDXC) Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ChromaDex Stock Performance

Shares of ChromaDex stock traded down $0.26 during trading hours on Friday, hitting $6.12. The company’s stock had a trading volume of 685,166 shares, compared to its average volume of 549,869. The business has a 50 day moving average price of $5.66 and a two-hundred day moving average price of $3.97. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $7.97. The company has a market cap of $467.45 million, a PE ratio of 612.61 and a beta of 2.16.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same period last year, the company posted ($0.01) earnings per share. As a group, research analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently made changes to their positions in CDXC. BSW Wealth Partners purchased a new stake in shares of ChromaDex in the third quarter valued at about $324,000. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex during the second quarter worth approximately $597,000. Marshall Wace LLP acquired a new stake in ChromaDex in the second quarter valued at approximately $56,000. Renaissance Technologies LLC lifted its stake in ChromaDex by 8.4% in the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock worth $1,136,000 after acquiring an additional 32,400 shares during the last quarter. Finally, Merriman Wealth Management LLC acquired a new position in ChromaDex during the 2nd quarter worth approximately $32,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Wall Street Analyst Weigh In

CDXC has been the subject of a number of recent research reports. Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, HC Wainwright raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.